Literature DB >> 7692305

Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen.

S Brocke1, A Gaur, C Piercy, A Gautam, K Gijbels, C G Fathman, L Steinman.   

Abstract

The role of infection in the pathogenesis of clinical relapses that occur in most autoimmune diseases, including multiple sclerosis, remains to be established. Experimental autoimmune encephalomyelitis (EAE) serves as a model for multiple sclerosis, with episodes of relapsing paralysis. In certain strains of mice, T-lymphocytes expressing the V beta 8 T-cell receptor (TCR) engage the amino-terminal epitope Ac1-11 of myelin basic protein, leading to EAE. The bacterial superantigen staphylococcal enterotoxin B (SEB) activates V beta 8-expressing T cells. Here we show that after immunization with Ac1-11, or after transfer of encephalitogenic T-cell lines or clones reactive to Ac1-11, SEB induces exacerbation or relapses of paralytic disease in mice that are in clinical remission following an initial episode of paralysis, and triggers paralysis in mice with subclinical disease. Tumour necrosis factor has a critical role in the mechanism underlying SEB-induced exacerbation of disease, because anti-tumour necrosis factor antibody given in vivo delays the onset of paralysis triggered by SEB. On reactivation of autoaggressive cells through their T-cell receptor, superantigens may induce clinical relapses of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692305     DOI: 10.1038/365642a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

Review 1.  Immune response to staphylococcal superantigens.

Authors:  T Krakauer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  Mechanisms for the induction of autoimmunity by infectious agents.

Authors:  K W Wucherpfennig
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

4.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

6.  Staphylococcal enterotoxin B-specific adhesion of murine splenic T cells to a human endothelial cell line.

Authors:  M Kita; K Eguchi; Y Kawabe; T Tsukada; K Migita; A Kawakami; N Matsuoka; S Nagataki
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

7.  Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis.

Authors:  I J Simpson; M A Skinner; A Geursen; J S Peake; W G Abbott; J D Fraser; C M Lockwood; P L Tan
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 8.  Superantigens in demyelinating disease.

Authors:  S Brocke; C Piercy; L Steinman
Journal:  Springer Semin Immunopathol       Date:  1996

9.  Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigen.

Authors:  J M Soos; A C Hobeika; E J Butfiloski; J Schiffenbauer; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.

Authors:  D J Berg; R Kühn; K Rajewsky; W Müller; S Menon; N Davidson; G Grünig; D Rennick
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.